Healthy adults
Conditions
Interventions
Take 20 ml of test drink daily immediately after waking up.
Take 20 ml of placebo daily immediately after waking up.
Sponsors
IMEQRD Co., Ltd
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.20 to 59 years old (at the time of submission of an informed consent document) 2.Healthy adults (who were judged as healthy individuals by the principal investigator) 3.Men and women 4.Those with subjective symptoms of eye fatigue 5.Non-smokers 6.Smartphone users (who can use electronic diaries) 7.Those who do not change their prescription of eyeglasses or contact lenses during the study period 8.Those who can continue to take test food for 3 months 9.Those who can provide their written informed consent
Exclusion criteria
Exclusion criteria: 1.Those who currently receive some types of drug treatment (except for the drugs that are taken as needed) 2.Those who currently undergo dietary or exercise therapy under the supervision of a physician 3.Those with a history of treatment for malignant tumor, heart failure, or heart attack 4.Those who have undergone gastrointestinal surgery (except for appendectomy) 5.Those with a past medical history of any of the following: hepatic or other major disorders (kidneys, endocrine, cardiovascular, gastrointestine, lungs, blood, and metabolism), or complications of the disorders listed above 6.Those who have undergone laser-assisted in-situ keratomileusis in the past six months 7.Those with eye diseases, except for ametropia (hyperopia, myopia, and astigmatism) 8.Those who currently take health food (such as food products to maintain or restore health and supplements) 9.Those with a past and current medical history of drug or food allergy 10.Those who work irregularly, such as night shifts and irregular shifts 11.Those who have participated in another clinical trial within a month prior to submission of an informed consent document 12.Those who are currently pregnant or breastfeeding and those who desire a pregnancy 13.In the opinion of the principal investigator, those who were determined to be unsuitable for participation in this clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eye fatigue measurement (high-frequency component-1) | — |
Secondary
| Measure | Time frame |
|---|---|
| Macular pigment optical density measurement, Contrast sensitivity measurement , Eye test, Subjective symptoms questionnaire to assess eye symptoms , Bowel habit questionnaire, Blood flow measurement | — |
Countries
Japan
Contacts
Public ContactYoshitada Hira
IMEQRD Co., Ltd Planning and Sales Department
Outcome results
None listed